{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:43:56Z","timestamp":1780512236712,"version":"3.54.1"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.557928","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T05:52:54Z","timestamp":1602049974000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["From the Gut to the Brain and Back: Therapeutic Approaches for the Treatment of Network Dysfunction in Parkinson's Disease"],"prefix":"10.3389","volume":"11","author":[{"given":"Giovanna","family":"Paolone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S1474-4422(06)70600-7","article-title":"A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance","volume":"5","author":"Calabresi","year":"2006","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.nbd.2017.10.010","article-title":"Chemogenetic modulation of cholinergic interneurons reveals their regulating role on the direct and indirect output pathways from the striatum","volume":"109","author":"Aldrin-Kirk","year":"2018","journal-title":"Neurobiol Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1002\/mds.26326","article-title":"Eltoprazine prevents dyskinesias by reducing striatal glutamate and direct pathway neuron activity","volume":"30","author":"Paolone","year":"2015","journal-title":"Mov Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7742(08)60277-9","article-title":"Animal models of parkinsonism using selective neurotoxins: clinical and basic implications","volume":"31","author":"Zigmond","year":"1989","journal-title":"Int Rev Neurobiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF03033565","article-title":"The 6-hydroxydopamine model of Parkinson's disease","volume":"11","author":"Simola","year":"2007","journal-title":"Neurotox Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur J Neurosci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.nbd.2004.01.007","article-title":"A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function","volume":"16","author":"Lundblad","year":"2004","journal-title":"Neurobiol Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.bbr.2009.12.048","article-title":"The cholinergic system and Parkinson disease","volume":"221","author":"Bohnen","year":"2009","journal-title":"Behav Brain Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13670-018-0234-4","article-title":"Recent advances in cholinergic imaging and cognitive decline-Revisiting the cholinergic hypothesis of dementia","volume":"7","author":"Bohnen","year":"2018","journal-title":"Curr Geriatr Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1002\/mds.23932","article-title":"The interplay of cholinergic function, attention, and falls in Parkinson's disease","volume":"26","author":"Yarnall","year":"2011","journal-title":"Mov Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/bs.irn.2018.07.027","article-title":"Molecular imaging of the cholinergic system in Parkinson's disease","volume":"141","author":"Bohnen","year":"2018","journal-title":"Int Rev Neurobiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"16522","DOI":"10.1523\/JNEUROSCI.2545-13.2013","article-title":"Attention, movement control, and fall propensity: analysis of multi-system model of Parkinson\u2018s disease using a novel behavioral test system for the assessment of deficits in the cognitive control of gait, balance and complex movement in rats","volume":"33","author":"Kucinski","year":"2013","journal-title":"J Neurosci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging."},{"key":"B14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinson's disease-related pathology","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","article-title":"Transneuronal propagation of pathologic alpha synuclein from the gut to the brain models Parkinson's disease","volume":"103","author":"Kim","year":"2019","journal-title":"Neuron."},{"key":"B16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.parkreldis.2019.05.006","article-title":"Four-week trunk-specific exercise program decreases forward trunk flexion in Parkinson's disease: a single-blinded, randomized controlled trial","volume":"64","author":"Gandolfi","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.05.004","article-title":"A physical therapy programme for functional motor symptoms: a telemedicine pilot study","author":"Demartini","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"B18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/mds.20394","article-title":"Striatal synaptic plasticity: implications for motor learning and Parkinson's disease","volume":"20","author":"Pisani","year":"2005","journal-title":"Mov Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.neuron.2015.07.019","article-title":"Habit Learning by naive macaques is marked by response sharpening of striatal neurons representing the cost and outcome of acquired action sequences","volume":"87","author":"Desrochers","year":"2015","journal-title":"Neuron."},{"key":"B20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1152\/physiol.00004.2012","article-title":"Striatal mechanisms underlying movement, reinforcement, and punishment","volume":"27","author":"Kravitz","year":"2012","journal-title":"Physiology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.celrep.2018.11.053","article-title":"dopamine cells differentially regulate striatal cholinergic transmission across regions through corelease of dopamine and glutamate","volume":"25","author":"Cai","year":"2018","journal-title":"Cell Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1073\/pnas.88.10.4205","article-title":"Phenotypical characterization of the rat striatal neurons expressing the d1 dopamine receptor gene","volume":"88","author":"Le Moine","year":"1991","journal-title":"Proc Natl Acad Sci USA."},{"key":"B23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0304-3940(90)90671-U","article-title":"D2 dopamine receptor gene expression by cholinergic neurons in the rat striatum","volume":"117","author":"Le Moine","year":"1990","journal-title":"Neurosci Lett."},{"key":"B24","doi-asserted-by":"publisher","first-page":"10289","DOI":"10.1523\/JNEUROSCI.2155-04.2004","article-title":"D2 dopamine receptor-mediated modulation of voltage-dependent na+ channels reduces autonomous activity in striatal cholinergic interneurons","volume":"24","author":"Maurice","year":"2004","journal-title":"J Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/cne.1345","article-title":"Presynaptic localisation of the nicotinic acetylcholine receptor beta2 subunit immunoreactivity in rat nigrostriatal dopaminergic neurones","volume":"439","author":"Jones","year":"2001","journal-title":"J Comp Neur."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/nn769","article-title":"Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum","volume":"4","author":"Zhou","year":"2001","journal-title":"Nat Neurosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nn1244","article-title":"Nicotine amplifies reward-related dopamine signals in striatum","volume":"7","author":"Rice","year":"2004","journal-title":"Nat Neurosci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.celrep.2012.05.011","article-title":"Selective activation of cholinergic interneurons enhances accumbal phasic dopamine release: setting the tone for reward processing","volume":"2","author":"Cachope","year":"2012","journal-title":"Cell Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/mds.27740","article-title":"Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders","volume":"34","author":"Moehle","year":"2019","journal-title":"Mov Disord."},{"key":"B30","doi-asserted-by":"publisher","first-page":"9161","DOI":"10.1523\/JNEUROSCI.0873-16.2016","article-title":"Involvement of striatal cholinergic interneurons and m1 and m4 muscarinic receptors in motor symptoms of Parkinson's disease","volume":"36","author":"Ztaou","year":"2016","journal-title":"J Neurosci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"ENEURO","DOI":"10.1523\/ENEURO.0397-17.2018","article-title":"Targeted activation of cholinergic interneurons accounts for the modulation of dopamine by striatal nicotinic receptors","volume":"5","author":"Brimblecombe","year":"2018","journal-title":"eNeuro"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1523\/JNEUROSCI.5071-13.2014","article-title":"A major external source of cholinergic innervation of the striatum and nucleus accumbens originates in the brainstem","volume":"34","author":"Dautan","year":"2014","journal-title":"J Neurosci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.neuroimage.2017.02.006","article-title":"Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: evidence from Parkinson's disease patients with defined cholinergic losses","volume":"149","author":"Kim","year":"2017","journal-title":"Neuroimage"},{"key":"B34","doi-asserted-by":"publisher","first-page":"S259","DOI":"10.1016\/S1353-8020(08)70013-0","article-title":"Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits","volume":"13","author":"Calabresi","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41467-018-03802-y","article-title":"GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease","volume":"9","author":"Lozovaya","year":"2018","journal-title":"Nat Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.15698\/cst2018.06.142","article-title":"Striatal dual cholinergic \/GABAergic transmission in Parkinson disease: friends or foes?","volume":"2","author":"Lozovaya","year":"2018","journal-title":"Cell Stress"},{"key":"B37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1037\/e472122004-001","article-title":"Brain monoamines and Parkinsonism","volume":"3","author":"Hornykiewicz","year":"1975","journal-title":"Natl Inst Drug Abuse Res Monogr Ser"},{"key":"B38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/ana.410150503","article-title":"Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease","volume":"15","author":"Nakano","year":"1984","journal-title":"Ann Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuropsychologia.2014.06.013","article-title":"The contribution of acetylcholine and dopamine to subprocesses of visual working memory \u2013 what patients with amnestic mild cognitive impairment and Parkinson's disease can tell us","volume":"61","author":"Blatt","year":"2014","journal-title":"Neuropsychologia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuroimage.2018.01.021","article-title":"Compensatory dopaminergic-cholinergic interactions in conflict processing: evidence from patients with Parkinson's disease","volume":"190","author":"Kim","year":"2019","journal-title":"Neuroimage"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1523\/JNEUROSCI.12-11-04224.1992","article-title":"Long-term synaptic depression in the striatum: physiological and pharmacological characterization","volume":"12","author":"Calabresi","year":"1992","journal-title":"J Neurosci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00213-018-5150-y","article-title":"Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease","volume":"236","author":"Koshy Cherian","year":"2019","journal-title":"Psychopharmacology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1755-5949.2010.00166.x","article-title":"Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data","volume":"17","author":"van Laar","year":"2010","journal-title":"CNS Neurosci Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1255555","DOI":"10.1126\/science.1255555","article-title":"Neurodegeneration. Alzheimer's and Parkinson's diseases: the The prion concept in relation to assembled A\u03b2, tau, and \u03b1-synuclein","volume":"349","author":"Goedert","year":"2015","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neulet.2005.11.012","article-title":"Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology","volume":"396","author":"Braak","year":"2006","journal-title":"Neurosci Lett."},{"key":"B46","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.1007\/s12035-018-0937-8","article-title":"Bidirectional neural interaction between central dopaminergic and gut lesions in Parkinson's disease models","volume":"55","author":"Garrido-Gil","year":"2018","journal-title":"Mol Neurobiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature."},{"key":"B48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bbr.2006.04.025","article-title":"Olfactory discrimination deficits in mice lacking the dopamine transporter or the D2 dopamine receptor","volume":"172","author":"Tillerson","year":"2006","journal-title":"Behav Brain Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/jnen\/62.12.1241","article-title":"Morphogenesis of Lewy bodies: dissimilar incorporation of -synuclein, ubiquitin, and p62","volume":"62","author":"Kuusisto","year":"2003","journal-title":"J Neuropathol Exp Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(04)00740-9","article-title":"Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough","volume":"3","author":"Lang","year":"2004","journal-title":"Lancet Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00401-016-1661-y","article-title":"Brain-to-stomach transfer of alpha-synuclein via vagal preganglionic projections","volume":"133","author":"Ulusoy","year":"2017","journal-title":"Acta Neuropathol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","article-title":"Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen","volume":"110","author":"Braak","year":"2003","journal-title":"J Neural Trans"},{"key":"B53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40478-016-0305-8","article-title":"Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies","volume":"4","author":"Corbille","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"B54","volume-title":"Momoires of a Stomach","author":"Sydney","year":"1850"},{"key":"B55","doi-asserted-by":"publisher","first-page":"eaat5236","DOI":"10.1126\/science.aat5236","article-title":"A gut-brain neural circuit for nutrient sensory transduction","volume":"361","author":"Kaelberer","year":"2018","journal-title":"Science."},{"key":"B56","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/ene.12753","article-title":"Can we use peripheral tissue biopsies to diagnose Parkinson's disease? A review of the literature","volume":"23","author":"Schneider","year":"2016","journal-title":"Eur J Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0140-6736(95)92707-7","article-title":"Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation","volume":"346","author":"Singaram","year":"1995","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1126\/science.275.5301.838","article-title":"Dopaminergic neurons protected from degeneration by GDNF gene therapy","volume":"275","author":"Choi-Lundberg","year":"1997","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/brain\/awz023","article-title":"Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease","volume":"142","author":"Whone","year":"2019","journal-title":"Brain"},{"key":"B60","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41582-019-0180-6","article-title":"Parkinson disease and growth factors \u2013 is GDNF good enough?","volume":"15","author":"Kirkeby","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.gt.3301682","article-title":"Delayed delivery of AAV GDNF prevents nigral neurodegeneration and promotes functionalrecovery in a rat model of Parkinson's disease","volume":"9","author":"Wang","year":"2002","journal-title":"Gene Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1111\/j.1460-9568.2005.04414.x","article-title":"Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model","volume":"22","author":"Dowd","year":"2005","journal-title":"Eur J Neurosci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral delivery of GDNF in primate models of Parkinson's disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science."},{"key":"B64","doi-asserted-by":"publisher","first-page":"4942","DOI":"10.1523\/JNEUROSCI.22-12-04942.2002","article-title":"Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration","volume":"22","author":"Palfi","year":"2002","journal-title":"J Neurosci"},{"key":"B65","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.expneurol.2007.08.019","article-title":"Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection in Parkinson's disease?","volume":"209","author":"Lindvall","year":"2008","journal-title":"Exp Neurol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.addr.2013.07.008","article-title":"Encapsulated cell therapy for neurodegenerative diseases: from promise to product","author":"Emerich","year":"2014","journal-title":"Adv Drug Deliv Rev."},{"key":"B67","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.tips.2015.05.003","article-title":"Cell encapsulation: technical and clinical advances","volume":"36","author":"Orive","year":"2015","journal-title":"Trends Pharmacol Sci."},{"key":"B68","first-page":"p. 85","article-title":"Cell therapy for epilepsy. In: Emerich DF, Orive G, editors","volume-title":"Cell Therapy","author":"Simonato","year":"2017"},{"key":"B69","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.omtm.2018.03.001","article-title":"Seizure-suppressant and neuroprotective effects of encapsulated BDNF-producing cells in a rat model of temporal lobe epilepsy","volume":"9","author":"Falcicchia","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B70","doi-asserted-by":"publisher","first-page":"6286197","DOI":"10.1155\/2019\/6286197","article-title":"Widespread striatal delivery of gdnf from encapsulated cells prevents the anatomical and functional consequences of excitotoxicity","volume":"11","author":"Emerich","year":"2019","journal-title":"Neural Plast."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1523\/JNEUROSCI.0435-18.2018","article-title":"Long-term, targeted delivery of GDNF from encapsulated cells is neuroprotective and reduces seizures in the pilocarpine model of epilepsy","volume":"39","author":"Paolone","year":"2019","journal-title":"J Neurosci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3171\/2012.2.JNS11714","article-title":"Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery","volume":"117","author":"Wahlberg","year":"2012","journal-title":"J Neurosurg."},{"key":"B73","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.crphar.2020.04.001","article-title":"Long-term, stable, targeted biodelivery and efficacy of gdnf from encapsulated cells in the rat and goettingen miniature pig brain","volume":"1","author":"Wahlberg","year":"2020","journal-title":"Curr Res Pharm."},{"key":"B74","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/096368970000900210","article-title":"The DaNeX study of embryonic mesencephalic, dopaminergic tissue grafted to a minipig model of Parkinson's disease: preliminary findings of effect of MPTP poisoning on striatal dopaminergic markers","volume":"9","author":"Danielsen","year":"2000","journal-title":"Cell Transplant"},{"key":"B75","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.expneurol.2012.02.012","article-title":"Comparison of the behavioral and histological characteristics of the 6-OHDA and \u03b1-synuclein rat models of Parkinson's disease","volume":"235","author":"Decressac","year":"2012","journal-title":"Exp Neurol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrn812","article-title":"The GDNF family: signalling, biological functions and therapeutic value","volume":"3","author":"Airaksinen","year":"2002","journal-title":"Nat Rev Neurosci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.expneurol.2005.03.006","article-title":"Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct","volume":"195","author":"Fjord-Larsen","year":"2005","journal-title":"Exp Neurol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/mds.21503","article-title":"Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys","volume":"22","author":"Herzog","year":"2007","journal-title":"Mov Disord."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Double-blind, sham-surgery controlled trial of gene delivery of AAV2-neurturin for Parkinson's disease","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.24436","article-title":"Gene delivery of neurturin to putamen and substantia nigra in parkinson disease: a double-blind, randomized, controlled trial","volume":"78","author":"Warren Olanow","year":"2015","journal-title":"Ann Neurol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.nbd.2015.03.023","article-title":"Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with \u03b1-synucleinopathies","volume":"78","author":"Bartus","year":"2015","journal-title":"Neurobiol Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/brain\/awaa020","article-title":"Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease","volume":"143","author":"Chu","year":"2020","journal-title":"Brain."},{"key":"B83","doi-asserted-by":"publisher","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B84","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron."},{"key":"B85","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41582-019-0205-1","article-title":"Alzheimer disease and aducanumab: adjusting our approach","volume":"15","author":"Selkoe","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"104587","DOI":"10.1016\/j.nbd.2019.104587","article-title":"Immunotherapy in Parkinson's disease: current status and future directions","volume":"132","author":"Chatterjee","year":"2019","journal-title":"Neurobiol Dis"},{"key":"B87","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J Neurosci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS ONE."},{"key":"B90","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-018-0276-2","article-title":"Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating alpha-synuclein transmission and neuroinflammation","volume":"13","author":"Kim","year":"2018","journal-title":"Mol Neurodegener."},{"key":"B91","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/mds.27959","article-title":"Dyskinesia matters","volume":"35","author":"Cenci","year":"2020","journal-title":"Mov Disord."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1212\/WNL.25.12.1144","article-title":"On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients","volume":"25","author":"Shoulson","year":"1975","journal-title":"Neurology."},{"key":"B97","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/mds.26078","article-title":"Novel formulations and modes of delivery of levodopa","volume":"30","author":"Poewe","year":"2015","journal-title":"Mov Disord."},{"key":"B98","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1038\/ctg.2016.19","article-title":"Long-term PEG-J tube safety in patients with advanced Parkinson's disease","volume":"7","author":"Epstein","year":"2016","journal-title":"Clin Transl Gastroenterol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s12325-019-01014-4","article-title":"current practices for outpatient initiation of levodopa-carbidopa intestinal gel for management of advanced Parkinson's disease in the United States","volume":"36","author":"Amjad","year":"2019","journal-title":"Adv Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3233\/JPD-191605","article-title":"Levodopa-carbidopa Intestinal gel monotherapy: GLORIA registry demographics, efficacy, and safety","volume":"9","author":"Poewe","year":"2019","journal-title":"J Parkinson's Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1007\/s10072-020-04401-w","article-title":"Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population","volume":"41","author":"Antonini","year":"2020","journal-title":"Neurol Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00702-019-02034-8","article-title":"Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation","volume":"126","author":"Richter","year":"2019","journal-title":"J Neural Transm."},{"key":"B103","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jns.2017.12.012","article-title":"Effects of intestinal levodopa infusion on freezing of gait in Parkinson disease","volume":"385","author":"Zibetti","year":"2018","journal-title":"J Neurol Sci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/mdc3.12640","article-title":"Levodopa\/carbidopa intestinal gel infusion therapy: focus on gait and balance","volume":"5","author":"Rispoli","year":"2018","journal-title":"Mov Disord Clin Pract."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1007\/s00415-019-09337-6","article-title":"Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa\/carbidopa intestinal gel: final results of the GREENFIELD observational study","volume":"266","author":"Modugno","year":"2019","journal-title":"J Neurol."},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10018-y","article-title":"Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of oral vs intrajejunal levodopa","author":"Kulisevsky","year":"2020","journal-title":"J Neurol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"S1353","DOI":"10.1016\/j.parkreldis.2020.05.001","article-title":"Clinical implications of gastric complications on levodopa treatment in Parkinson's disease","volume":"11","author":"Petzinger","year":"2020","journal-title":"Parkinsonism Relat Disord."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord."},{"key":"B109","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000008699","article-title":"Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease","volume":"94","author":"Feustel","year":"2020","journal-title":"Neurology."},{"key":"B110","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nrn1970","article-title":"Enriched environments, experience-dependent plasticity and disorders of the nervous system","volume":"7","author":"Nithianantharajah","year":"2006","journal-title":"Nat Rev Neurosci."},{"key":"B111","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.neuropharm.2012.06.029","article-title":"Enhancement of cognitive function in models of brain disease through environmental enrichment and physical activity","volume":"64","author":"Pang","year":"2013","journal-title":"Neuropharmacology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12031-016-0831-7","article-title":"Cholinergic and dopaminergic alterations in nigrostriatal neurons are involved in environmental enrichment motor protection in a mouse model of Parkinson's Disease","volume":"60","author":"Hilario","year":"2016","journal-title":"J Mol Neurosci"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/4151030a","article-title":"Functional neurogenesis in the adult hippocampus","volume":"415","author":"van Praag","year":"2002","journal-title":"Nature."},{"key":"B114","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neuroscience.2010.08.008","article-title":"Angiogenesis but not neurogenesis is critical for normal learning and memory acquisition","volume":"171","author":"Kerr","year":"2010","journal-title":"Neuroscience"},{"key":"B115","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10571-009-9488-x","article-title":"Biological mechanisms of physical activity in preventing cognitive decline","volume":"30","author":"Lista","year":"2010","journal-title":"Cell Mol Neurobiol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00702-010-0474-8","article-title":"Running wheel activity restores MPTP-induced functional deficits","volume":"118","author":"Fredriksson","year":"2011","journal-title":"J Neural Transm."},{"key":"B117","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1038\/s41598-018-22462-y","article-title":"Exercise ameliorates motor deficits and improves dopaminergic functions in the rat hemi-Parkinson's model","volume":"8","author":"Chen","year":"2018","journal-title":"Sci Rep."},{"key":"B118","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.parkreldis.2019.10.024","article-title":"Validity of the wall goniometer as a screening tool to detect postural abnormalities in Parkinson's disease","volume":"69","author":"Tinazzi","year":"2019","journal-title":"Parkinsonism Relat Disord."},{"key":"B119","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/jnnp-2014-310049","article-title":"Camptocormia in Parkinson's disease: definition, epidemiology, pathogenesis treatment modalities","volume":"87","author":"Srivanitchapoom","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3389\/fneur.2019.01254","article-title":"The effect of medication and deep brain stimulation on posture in parkinson's disease","volume":"10","author":"Schlenstedt","year":"2019","journal-title":"Front Neurol."},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.01.012","article-title":"Quantitative assessment of posture in healthy controls and patients with Parkinson's disease","author":"Schlenstedt","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"B122","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1474-4422(11)70067-9","article-title":"Postural deformities in Parkinson's disease","volume":"10","author":"Doherty","year":"2011","journal-title":"Lancet Neurol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.parkreldis.2018.04.033","article-title":"Diagnostic criteria for camptocormia in Parkinson's disease: a consensus-based proposal","volume":"53","author":"Fasano","year":"2018","journal-title":"Park Relat Disord."},{"key":"B124","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.parkreldis.2019.11.014","article-title":"Applicability of the wall goniometer in Parkinson's disease","volume":"69","author":"Orcioli-Silva","year":"2019","journal-title":"Parkinsonism Relat Disord."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.557928\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T05:52:57Z","timestamp":1602049977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.557928\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":124,"alternative-id":["10.3389\/fneur.2020.557928"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.557928","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"article-number":"557928"}}